mefloquine has been researched along with adenosine in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brown, RE; Emery, CE; Prichard, DA; Stancato, FA; Wolfe, AD | 1 |
| Benwell, K; Cliffe, IA; Dourish, CT; Gillespie, RJ; Knight, AR; Lerpiniere, J; Misra, A; Pratt, RM; Revell, D; Upton, R; Weiss, SM | 1 |
| Kelley, M; Li, L; Vessey, DA | 1 |
1 review(s) available for mefloquine and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for mefloquine and adenosine
| Article | Year |
|---|---|
Arylmethanol and thiosemicarbazone influence of plasmodial macromolecular synthesis and cell stability.
Topics: Adenosine; Animals; Antimalarials; Erythrocytes; Macromolecular Substances; Mefloquine; Nucleic Acids; Phenanthrenes; Plasmodium berghei; Quinolines; Rats; Reticulocytes; Thiosemicarbazones | 1983 |
Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease.
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Evaluation, Preclinical; Humans; Ligands; Mefloquine; Mice; Motor Activity; Neuroprotective Agents; Parkinsonian Disorders; Phenethylamines; Purines; Pyrimidines; Radioligand Assay; Rats; Triazines; Triazoles | 2003 |
Pannexin-I/P2X 7 purinergic receptor channels mediate the release of cardioprotectants induced by ischemic pre- and postconditioning.
Topics: Adenosine; Adenosine Triphosphate; Animals; Carbenoxolone; Connexins; Ischemic Preconditioning, Myocardial; Lysophospholipids; Mefloquine; Myocardial Reperfusion Injury; Nerve Tissue Proteins; Purinergic P2 Receptor Antagonists; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Rosaniline Dyes; Sphingosine | 2010 |